Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal
Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.
|Study Design:||Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal|
|Study Start Date:||April 2006|
|Estimated Primary Completion Date:||December 2006 (Final data collection date for primary outcome measure)|
First episode patients have a greater potential for therapeutic response than multi-episode patients, and many of them also havea great desire to rejoin the workforce. Unfortunately, first episode patients become non-compliant or intermittently compliant with prescribed antipsychotic treatment at least as frequently as multi-episode patients. We believe that assured treatment with Risperal CONTSTA will provide first episode patients wiwth their best opporutnity for continued improvement in cognitive function beyond 3 months of treatment and that improvements in cognitive function will be associated with a greater likelihood of employment, real-world outcomes, such as independent living, as well as measures of brain function.
|United States, North Carolina|
|John Umstead Hospital|
|Butner, North Carolina, United States, 27509|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||William H Wilson, PhD||Duke University|
|Principal Investigator:||Joseph P McEvoy, MD||Duke University|